IGIrfan Gahramanov

Irfan Gahramanov

*This is an algorithmically generated author record based on publicly available information.

Irfan Gahramanov has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-Term outcomes of mild traumatic brain injury in veterans of the second Nagorno-Karabakh war

    by Javid Shafiyev, Anar İsMayılov, Azar Aliyev, Rashad Qubadov, Irfan Gahramanov

    Objectives This study aimed to investigate the types, frequency, and longitudinal course of post-concussive symptoms (PCS) in veterans diagnosed with mild traumatic brain injury (mTBI) during the Second Nagorno-Karabakh War, with a particular focus on persistent post-concussive symptoms (PPCS) and their association with blast exposure, loss of consciousness (LOC), and alteration of consciousness (AOC). Methods A total of 1,280 male veterans with documented mTBI diagnoses were included. Participants were divided into blast-related and non-blast groups. PCS including headache, memory impairment, dizziness, tinnitus, sleep disturbances, and irritability were tracked at six time points (from week 1 to beyond 12 months). Individuals diagnosed with posttraumatic stress disorder (PTSD) were excluded to reduce diagnostic overlap. PPCS was defined as the presence of at least one symptom persisting beyond 3 months post-injury. Generalized Estimating Equations (GEE) were used to analyze symptom trajectories, and the effects of LOC and AOC on symptom persistence were assessed. Results Blast exposure was significantly associated with higher early PCS rates. Symptoms such as memory impairment, dizziness, sleep disturbances, and irritability were more persistent in the blast group. AOC was more strongly associated with the development of PPCS than LOC, particularly in relation to dizziness, tinnitus, and sleep disturbances. Sleep disturbances (39.8%) and tinnitus (28.1%) were the most common persistent symptoms. LOC was not a significant predictor of long-term symptom persistence. Conclusion Blast-related mTBI, especially when accompanied by AOC, is strongly associated with persistent post-concussive symptoms, independent of PTSD. AOC emerged as a more robust predictor of delayed recovery than LOC. These findings suggest that the persistence of PCS may reflect underlying neurophysiological effects of blast injury, not merely psychological stress. Long-term monitoring and targeted rehabilitation strategies are warranted for affected individuals.


  • Evaluating duloxetine for pruritus and psychiatric comorbidities in lichen simplex chronicus

    by Javid Shafiyev, Irfan Gahramanov

    The use of antidepressant medications in the treatment of lichen simplex chronicus (LSC) also known as neurodermatitis, is not well-documented in the literature. The primary aim of our study is to evaluate the impact of duloxetine 30 mg on the quality of life in patients with LSC, focusing on both pruritus and psychopathological aspects. The secondary aim is to investigate the relationship between LSC and anxiety and depression. The observational prospective clinical study, conducted from November 2023 to November 2024, included male and female patients aged 18 and older diagnosed with neurodermatitis (lichen simplex chronicus). Inclusion criteria required a confirmed diagnosis by a dermatologist. Exclusion criteria included other skin conditions, polyneuropathies (e.g., diabetic, chemotherapy-induced), malignancy, current use of antidepressants or neuropathic pain medications, and medications known to cause itching (e.g., β-blockers, ACE inhibitors, antacids). Patients with LSC at the dermatology clinic were assessed by a dermatologist using the DLQI and a neurologist using the Beck Depression and Anxiety Inventory before and after three months of treatment. The study included 219 patients with a mean age of 39.6 (12.2) years, 69.5% female and 30.5% male. Post-treatment, the Duloxetine 30 mg + 0.05% alpha clobetasol propionate group showed the most significant improvement in DLQI scores (p < 0.05). This group also had a notable reduction in itchiness scores by the third month, with more change over time. The greatest reduction in scores on the Beck Depression Inventory-II and Beck Anxiety Inventory was observed in the Duloxetine 30 mg + 0.05% alpha-clobetasol propionate group, with this reduction continuing in a decreasing pattern in the Duloxetine 30 mg and 0.05% alpha-clobetasol propionate groups, respectively. Significant changes in the time-group interaction were observed only in the Duloxetine 30 mg + 0.05% alpha-clobetasol propionate and Duloxetine 30 mg groups (p < 0.05). No significant time effect was seen in the 0.05% alpha clobetasol propionate group. In the regression analysis, both BAI and BDI-II showed significant and strong effects on DLQI (p < 0.05). Our study suggests that duloxetine 30 mg may be effective in treating LSC by reducing pruritus and addressing comorbid psychiatric conditions like anxiety and depression. The multidisciplinary approach, involving both dermatological and neuropsychiatric evaluations, is essential for treatment. Long-term, multicenter studies are needed to confirm these findings.